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Background: Despite adequate treatment, up to 30% of treated antihypertensive patients with primary, uncomplicated
hypertension remain uncontrolled. We proposed that high intracellular activity of the ATP regenerating enzyme creatine
kinase (CK) increases pressor responses and hypertension risk. In line with this, we found that plasma CK activity after rest, a
surrogate measure of tissue activity, is the main predictor of blood pressure levels and failure of antihypertensive therapy in
the general population. In addition, the creatine analog and competitive oral creatine kinase inhibitor beta-guanidinopropionic
acid effectively and safely reduced blood pressure in the spontaneously hypertensive rat. However, to our knowledge
there are no human data on the safety of oral supplementation with this substance. Therefore, we will assess the
tolerability of beta-guanidinopropionic acid in men, compared to creatine and placebo.
Methods/Design: This is a randomized, active and placebo controlled, triple blind, double dummy, single center
clinical intervention trial in 24 healthy male volunteers, 18 to 50 years old, recruited in the Netherlands. The
intervention consists of one week of daily oral administration of beta-guanidinopropionic acid 100 mg, creatine 5 gram,
or placebo. The primary outcome is the tolerability of beta-guanidinopropionic acid as a descriptive measure, in an
intent-to-treat analysis. Other outcomes include the placebo-adjusted differences with baseline in biochemical and
hemodynamic parameters, including plasma markers of muscle tissue damage, urine sodium excretion, resting sitting
systolic and diastolic brachial blood pressure, supine systolic and diastolic central blood pressure, pulse wave velocity
and augmentation index, heart rate, cardiac contractility, cardiac output, and total peripheral resistance.
Discussion: There is an unfulfilled need for new conservative options to treat resistant hypertension. This study will
provide first-in-men data on creatine kinase inhibition as a potential new class of antihypertensive drugs.
Trial registration: The Netherlands National Trial Register Trialregister.nl (identifier NTR 4444), registered 9 March 2014.
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Figure 1 Structural analogy between creatine and beta-
guanidinopropionic acid. Legend: Creatine (a) and beta-
guanidinopropionic acid (b) have an identical molecular formula
(C4H9N3O2), but creatine is methylated on its tertiary nitrogen, while
in beta-guanidinopropionic acid, the methyl group is positioned in
the carbon chain [16].
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Blood pressure reduction may be challenging despite the
availability of several classes of antihypertensive drugs
[1-5]. A substantial proportion of treated hypertensive
patients, up to 30% or more does not achieve blood
pressure control. Risk factors for poor control include
obesity, age, African ancestry, the presence of diabetes
or end organ damage; but non-adherence of the patient,
the white-coat effect, therapeutic inertia of the physician,
or the concomitant use of blood pressure increasing drugs
may also contribute. However, a subgroup of patients with
uncomplicated, primary hypertension remains who are
uncontrolled despite adequate use of antihypertensive
drugs [1-5]. The underlying pathophysiology in these pa-
tients is thought to be refractory to currently available
drugs, causing early heart disease, stroke, and early mor-
tality. Hence, the current scientific challenge is to develop
new conservative options to lower blood pressure [1-5].
We showed in a random, multi-ethnic population
sample that plasma CK activity after rest, a surrogate
measure of tissue CK, is the main predictor of blood
pressure, with a crude increase in blood pressure of
14 mm Hg systolic and 8 mm Hg diastolic per log CK
increase [6]. Although plasma and tissue CK activity were
found to be higher in men, subjects of African ancestry,
and obese patients [6,7], the association was independent
of sex, body mass index (BMI), or ethnicity. Therefore, we
proposed that high tissue CK might increase pressor
responses [6].
Cytosolic CK is tightly bound in the immediate proxim-
ity of ATP-utilizing enzymes such as Na+/K+-ATPase,
Ca2+-ATPase, and myosin ATPase. Here, ATP synthesized
by CK is preferentially used to fuel highly energy-
demanding processes such as sodium retention, cardio-
vascular contractility, as well as remodeling of arteries,
promoting hypertension [6,8]. Importantly, in accord with
a causal relationship, high tissue CK preceded hyper-
tension in animal models [9,10], as was found with high
plasma CK in humans [11], and inhibition of intracellular
CK substantially inhibited human vascular contractility
in vitro [12]. Furthermore, vascular CK gene expression
was strongly associated with clinical blood pressure in
humans [13], and high plasma CK was found to be the
main predictor of failure of antihypertensive therapy in
the general population [5,14]. Finally, we recently showed
in a randomized control trial of 16-week-old male
spontaneously hypertensive rats versus controls (n = 16),
that oral CK inhibition with the competitive CK inhibitor
beta-guanidinopropionic acid (GPA) 3%, added to rat
chow over 4 weeks, safely reduced blood pressure. With a
systolic and diastolic baseline blood pressure of respect-
ively 191.5 (SE 4.3) and 143.1 (SE 4.1) mm Hg, GPA
significantly reduced blood pressure compared to controls
by 42.7 (5.5) systolic and 35.3 (4.8) mm Hg diastolic(P < 0.001), respectively [15]. To our knowledge, there are
no human data on the safety and effects of this potential
new antihypertensive agent; we will assess the tolerability




GPA or N-(aminoiminomethyl)-beta-alanine; (Cq4H9N3O2),
is a structural isomer of creatine (Figure 1) [16]. GPA is
generated in vivo via transamidination of β-alanine
(Figure 2) [17-19]. The physiological concentration in
human plasma is reported to range from trace amounts to
1.40 μmol/L [20,21]. Clearance is probably renal, akin to
creatine, creatinine, and other guanidino compounds
[17,19-21].
Despite the lack of human data on efficacy and side
effects, GPA is available as a food-supplement, usually in
doses of 500 mg, and is used by sportspersons to induce
endurance capacity and promote weight loss [16]. GPA
acts as a competitive inhibitor of cellular creatine up-
take, and attenuates the flux through the cytoplasmic
creatine kinase reaction [15,16,18]. CK catalyses the
rapid and reversible transfer of a phosphoryl group from
creatine phosphate to ADP, thereby forming creatine
and ATP:
ADP þ creatine phosphate <¼> ATP þ creatine:
The flux through the CK reaction is linearly correlated









Figure 2 Pathways of guanidino compound synthesis. Legend:
Guanidino compounds such as beta-guanidinopropionic acid, creatine,
guanidinoacetic acid, gamma-guanidinobutyric acid, and guanidinosuccinic
acid, are reported to be synthesized via transamidination of the amidino
group from arginine as the major pathway, or through the urea cycle.
Creatine biosynthesis involves two sequential steps catalyzed by
L-arginine:glycine amidinotransferase (AGAT), and S-adenosylmethionine:
guanidinoacetate N-methyltransferase (GAMT) After [17-19].
Karamat et al. Trials  (2015) 16:56 Page 3 of 9Nuclear genes encode four CK subunits or monomers:
cytoplasmic muscle (CKM), cytoplasmic brain (CKB),
ubiquitous mitochondrial (CKMT1), and sarcomeric
mitochondrial (CKMT2). The enzymatic functional form
can be either a homodimer (BB and MM), a heterodimer
(MB), or an octamer (mitochondrial monomers), thus
creating five isoenzymes. The three dimeric cytoplasmic
CKMM, CKMB, and CKBB isoenzymes are pre-
dominantly expressed in striated skeletal and heart
muscle (MM), heart muscle (MB); and brain and smooth
muscle (BB). The two octameric mitochondrial CK iso-
enzymes are expressed in striated muscle and other tissue
[13]. The cytoplasmic isoenzymes appear in plasma of
healthy subjects, due to what is thought to be a non-
traumatic proportional release from tissue entering the
bloodstream through the lymphatic system [6]. Hence,
plasma CK is mainly the CKMM isoenzyme.
GPA is thought to inhibit cytoplasmic, but not mito-
chondrial CK [15,16,18]. Although GPA is phosphorylated
by cytoplasmic CK, both GPA and phosphorylated GPA
are 'inefficient substrates' for the CK reaction: in vitroVmax values are <1% of the Vmax values of creatine and
phosphocreatine [16,18,23]. Therefore, GPA may modu-
late the energy status of tissues, and we speculated that
this creatine analog may reduce blood pressure.
In animal studies, supplemental GPA (1 to 3%) in the
diet led to skeletal muscle changes similar to the adapta-
tions of endurance training [16]. In the unstressed heart,
left ventricular systolic pressure, cardiac output, and rate of
tension development were unchanged with GPA. During
high workload, studies showed unchanged or reduced peak
left ventricular-developed pressure and cardiac output.
However, blood pressure and peripheral hemodynamic
parameters were not an outcome in these studies [16]. We
recently showed that feeding 16-week-old spontaneously
hypertensive rats a diet containing 3% GPA reduced blood
pressure [15]. Importantly, the animals appeared healthy
after GPA [15,16], and the blood pressure-lowering effect
was reversible after withdrawal of the analog [15].
Manufacturing and testing
In accord with the definition for food supplements in
the legislation of the European Union [24], we consider
GPA as well as creatine to be food supplements, because
both are naturally occurring amino-acids. GPA is a white
crystalline tasteless powder, soluble in water. GPA pow-
der is ordered at Sequoia (Sequoia Research Products,
Oxford, UK). There are no reports or bans on this prod-
uct or the company to our knowledge, presented on the
FDA website using the FDA search engine, or online
with search engine Google, as of 20 February 2014. GPA,
creatine, and identical placebo capsules will be manufac-
tured by the Pharmacy & Pharmacology Department of
the Slotervaart Hospital, Amsterdam, The Netherlands.
This department is GMP certificated (ISO 9001:2001).
Product dossiers for GPA and creatine were written and
have received formal ethical approval by the AMC
Amsterdam Medical Ethics Review Committee (MERC).
GPA is marketed for human use in the U.S. and Australia,
but not in European countries. According to the legal
guidelines of the European Union, criteria of international
organs, generally accepted criteria, or national criteria are
approved when a supplement is not listed in the legislation
of the European Union.
Following the U.S. FDA guidelines [25], we first
qualified the supplier by establishing the reliability of the
supplier, with the methods mentioned above. Next, the
substance was tested for purity and for cyanide com-
pounds. Cyanide was not expected to be quantifiable
[26]. However, the cyano-group in cyanamide, one of the
compounds used in the formation of GPA, provides a
possible source of cyanide. We established in our certified
tests a purity of more than 99% (detection limit) and a
cyanide level lower than 1 p.p.m. (detection limit). Cyanide
occurs in many food items, with high concentrations in
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7,000 mg/kg (7 parts per thousand) [27].
In Europe, Annex II of Directive 88/388/EEC on fla-
vorings sets the following maximum levels for hydro-
cyanic acid in foodstuffs and beverages: 1 mg/kg in food
or beverages, with the exception of 50 mg/kg in nougat,
marzipan or similar products, and 5 mg/kg in canned
stone fruit [28]. With 100 mg GPA containing <1 p.p.m.
cyanide, the contribution to the daily intake will be <0.1
microgram/day.
Storage and distribution
GPA and creatine capsules will be stored at room
temperature. The participants will receive the test prod-
ucts at the hospital and will be instructed to store the
capsules at room temperature at home.
The test products will be labeled with a study number,
with the pharmacy holding the key to the content until
the end of the data collection.
Dose calculation
For GPA, we used the FDA guidance on Estimating the
Maximum Safe Starting Dose in Initial Clinical Trials in
Adult Healthy Volunteers [29]. This guidance outlines a
process for deriving the maximum recommended start-
ing dose for first-in-human clinical trials in adult healthy
volunteers, and recommends a standardized process by
which the maximum recommended starting dose can be
selected. The purpose of this process is to ensure the
safety of the human volunteers [29]. Toxicity should be
avoided at the initial clinical dose. However, doses
should be chosen that allow reasonably rapid attainment
of phase 1 trial objectives [29]. The major elements of
this process are as follows:
1. Determination of the no observed adverse effect
levels (NOAELs) in the tested animal species
2. Conversion of NOAELs to human equivalent doses
(HED)
3. Application of a safety factor.
1. No observed adverse effect level (NOAEL)
determination
In animal studies, GPA was administered through the
diet in concentrations of 1% or more over 8 weeks
without apparent adverse effects [16]. In animals weigh-
ing 200 grams eating 20 grams per day, we calculated a
'no observed adverse effect level' of 1,000 mg/kg/day.
Furthermore, in a patent application, Meglasson et al.
recommended a human dose of 1 to 500 mg/kg/day based
on his research in mice and rhesus monkeys [30]. In this
paper, rhesus monkeys weighing 9 kg were treated with
oral GPA 48 mg/kg/day (432 mg per monkey per day)
over 2 weeks without apparent adverse events.2. Conversion of the no observed adverse effect level
(NOAEL) to human equivalent dose (HED)
We converted the oral NOAELs in rats and monkeys
(resp. 1,000 mg/kg/day and 48 mg/kg/day) to oral HEDs
based on an algorithm proposed by the FDA based on
body surface area [29]. This algorithm proposes a conver-
sion factor from rat to human of 0.16 times the rat dose;
and of monkey to men of 0.32 the monkey dose (in mg/
kg/day; for a man of 60 kg) resulting in HEDs of resp.
160 mg/kg/day and 15 mg/kg/day for a man of 60 kg.
3. Application of a safety factor
A safety factor should be applied to the HED to increase
assurance that the first dose in humans will not cause
adverse effects. The use of the safety factor is based on
the possibility that humans may be more sensitive to the
toxic effects of a substance than predicted by the animal
models, that bioavailability may vary across species, and
that the models tested do not evaluate all possible hu-
man toxicities, or cannot be expressed by animals or
easily measured, such as headache or nausea. We con-
servatively chose 15 mg/kg/day oral dose for our final
calculations of the human dose, because this is the low-
est dose, and because of the closer allometric relation-
ship between monkey and man [29]. FDA advises a
safety factor of at least 10. Based on an average weight of a
male volunteer of 75 kg, we calculated a starting oral dose
for this phase 1 study of 75*1.5 mg/day = 112.5 mg/day;
we will use 100 mg/day.
Creatine
Creatine, which has an identical molecular formula as
GPA, was chosen to simultaneously assess the effect of
the synergist on peripheral hemodynamics. The average
daily rate of creatine synthesis in healthy omnivorous
males is estimated to be 1.3 g [31]. We will use 5 g as
recommended in studies on creatine supplementation.
No side effects are apparent at this dose [31,32].
Study design
We wrote the protocol using the SPIRIT '(Standard
Protocol Items: Recommendations for Interventional
Trials)' recommendations and the 'Template for Inter-
vention Description and Replication (TIDieR) checklist'
[33,34].
The ABC trial is a randomized, placebo and active
controlled, double-dummy, participant, intervention
provider, and outcome assessor (triple) blinded, parallel
group, single center (Academic Hospital of the Univer-
sity of Amsterdam), exploratory trial, with three arms: a
primary outcome of tolerability of GPA, in comparison
with creatine and placebo.
Randomization will be performed by an independent
party, the Clinical Pharmacy Unit of the Academic Hospital
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generated, nonadaptive, and restricted randomization
scheme and a 1:1:1 allocation ratio. The Pharmacy will gen-
erate the random allocation sequence. All participants who
give consent for participation and who fulfill the inclusion
criteria will be randomized to receive GPA 100 mg and cre-
atine placebo matching active creatine 5 gram; creatine 5
gram and GPA placebo matching GPA 100 mg; or double
dummy placebo over 1 week. The participant will receive
the blinded, randomized trial supplements from the phar-
macy. Allocation concealment will be ensured, as the
pharmacy will store the allocation list and not release the
randomization code until all outcome measures have
been assessed and the data bank has been closed. Thus,
randomization will be conducted without any influence
of the investigators, outcome assessors, or participant
characteristics. After assignment to interventions, trial
participants, trial staff, and the outcome assessor will
remain blinded to whether the participant was given a
placebo or a supplement until after all outcome data
have been assessed. Data analysis will be performed un-
blinded. We prespecified the use of accumulating data
to decide whether to stop the trial early, in case of serious
or unexpected side effects. Independent monitoring visits
will take place before the start of the trial, within 1 month
after initiation or after inclusion 5th subject; within
2 months after initiation or after inclusion 15th subject;
after last patient last visit; and after the data have been
entered into the database. Data entry will be verified by
two independent researchers. Budget administration is
by an independent organization (AMC Research BV,
Amsterdam, the Netherlands).
Objectives
The primary objective is to assess the tolerability of one
week of 100 mg oral GPA daily, as compared to placebo.
Secondary objectives include the comparison of toler-
ability with creatine, and the effect of one week of oral
GPA on hemodynamic parameters, including peripheral
and central blood pressure, and cardiac contractility as
compared to creatine and placebo. The tertiary objective
is to assess the effect of one week of oral administration
of GPA on biochemical parameters, including ADP-
induced platelet aggregation [35], compared to creatine
and placebo.
Eligibility
We will include healthy men aged 18 to 50 years, with a
normal, nonobese body mass (BMI 18.5 to 29.9 kg/m2).
Exclusion criteria include high blood pressure or the use
of antihypertensive drugs at baseline, (history of ) cardio-
vascular disease including TIA and stroke; the use of
plasma CK-increasing drugs including statins; use of
acetylsalicylic acid or nonsteroidal anti-inflammatorydrugs in the two weeks prior to the first visit; neuromus-
cular or endocrine disorders; vasculitis; HIV infection;
infectious hepatitis; personal or family history of bleed-
ing disorders; sickle cell anemia or other hereditary
anemia; smoking; current use or use within two months
prior to start of the trial of beta-guanidinopropionic acid
or creatine; and abnormalities in glucose, lipid spectrum,
thyroid, kidney, or liver biochemistry parameters in the
plasma. To stabilize and standardize plasma CK activity
during the trial, participants are instructed not to per-
form exercise three days prior to the baseline visit or
during the intervention in the first week [6].
Statistical analysis
Study outcomes
The primary outcome is the tolerability of GPA after
oral administration in healthy male volunteers versus
placebo as a descriptive measure, in an intent-to-treat
analysis. Other outcomes are to compare the tolerability
of GPA with creatine, and differences in hemodynamic
and biochemical parameters between treatment arms.
Sample size calculation
This is a first-in-man study with GPA, with allometric data
available from other species. According to the European
Medicines Agency (EMEA) guidelines [36], we will include
eight subjects in each arm, to assess the tolerability of
GPA versus placebo and creatine over one week.
Recruitment strategy
We will utilize two primary resources for identifying and
recruiting potential subjects: advertising and identifica-
tion in our Healthy Volunteer Research Database. The
advertisement has prior approval of the MERC. A dedi-
cated trial staff member will respond to inquiries about
participation in the trial on the same day, using a partici-
pant information letter approved by the MERC. Screening
will continue until the target population is achieved (24
subjects). The enrollment period is planned to extend over
9 months, until December 2014.
Clinical investigation
The participants will be instructed to come to the hos-
pital in the morning after an overnight fast for all visits
during the intervention, which is the first week of the
trial (Visit 1 to 5).
Intervention
The intervention will be provided under supervision of a
medical doctor. The duration of the intervention will be
7 days. To ensure intervention adherence, trial supple-
ments are ingested by the volunteer in the presence of
the trial staff during the hospital visits. In addition we
will use pill counts for the supplements taken at home.
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The time line is depicted in Figure 3. In brief, clinical
studies will be performed at baseline, and 1 day and
7 days after the trial supplements are used. The final as-
sessment of tolerability is at Day 21.
Questionnaire
The participants will receive a questionnaire to assess
tolerability at home during the week of intervention and
in the 2 weeks after the intervention. The questionnaire
encompasses the perceived side effects of the trial sup-
plements, using check boxes and free text space. The
questionnaire was piloted with healthcare professionals
and healthy volunteers.
Electrocardiography and Hemodynamics
On Day 0 (baseline), 1 (in the first hour after intake trial
supplements), 2 (after 1 day of trial supplements), and 8
(after 7 days of trial supplements) of the intervention
period, we will measure sitting brachial systolic and dia-
stolic blood pressure with an Omron M4 oscillometric
device (Omron Healthcare Europe BV, Hoofddorp, the
Netherlands) after 5 minutes of rest with an adjusted
cuff size on the left arm, at heart level. In addition, we
will perform electrocardiography (MAC 5000 Resting
ECG System; GE Healthcare; Boston, MA) and ambula-
tory 24-hour blood pressure monitoring (Spacelabs
90217 Ambulatory Blood Pressure Monitor, Spacelabs
Inc. Redmond, WA, USA). Furthermore, at baseline, Day
2, and Day 8, we will estimate central blood pressure,
pulse wave velocity, and the augmentation index with anFigure 3 Trial time line. Legend: The duration of the intervention is 7 day
inclusion, and randomization at Day 0 (baseline). After 24 h and 7 days of t
last visit at Day 21, to assess side effects.Arteriograph (Tensiomed Kft, Budapest, Hungary); and
heart rate, cardiac contractility, cardiac output, and total
peripheral resistance using a Nexfin BMEYE, (Amsterdam,
the Netherlands) blood-pressure monitor for continuous
noninvasive finger arterial blood pressure measurement.
Laboratory studies
All laboratory studies are after an overnight fast. At
baseline, we will assess plasma GPA, resting plasma CK
(after 3 days without heavy exercise), glucose, insulin,
lipid profile, creatine, creatinine, liver enzymes (ASAT,
ALAT, gamma GT), LDH, cardiac troponin, myoglobin,
TSH (to exclude subclinical hypothyroidism associated
with high plasma CK), sodium, potassium, platelet
count, coagulation tests (aPTT, PT), and ADP-induced
platelet aggregation (area under curve at final concentra-
tion ADP 0.1, 0.2, 0.5, 1, and 2 μmol/L). Furthermore, in
collected 24-h urine we will assess GPA, creatine, cre-
atinine, urea, sodium, and potassium. Tests will be re-
peated after 1 day and after 7 days of trial supplements,
with the exception of TSH, aPTT, and PT. ADP-induced
platelet aggregation will repeated at Day 8 only.
Concomitant care and interventions
There is no relevant concomitant care and no other in-
terventions are permitted during this trial of healthy
volunteers.
Safety
The investigator will inform the subjects and the MERC
if any event occurs, on the basis of which it appears thats. The trial supplements start at Day 1, after baseline measurements,
rial supplements, baseline measurements will be repeated, with the
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greater than was foreseen in the research proposal. The
study will be suspended pending further review by the
MERC, except insofar as suspension would jeopardize
the subjects’ health. The investigator will take care that
all subjects are kept informed.
Adverse and serious adverse events
We do not expect any adverse effects from this low dose
study. There are no FDA or other reports in formal or
informal sources on the side effects of ingestion of this
dose of GPA or creatine in animals or humans. There-
fore, a 1-day first-in-men study that we had proposed,
with hourly observation and physical and laboratory
examination of the subjects, was deemed unnecessary by
the MERC. Subjects with hypertension, a history of car-
diovascular, liver, or kidney disease, or with laboratory
abnormalities at baseline will be excluded. Adverse
events reported by the included subject spontaneously
or through the questionnaire, or observed by the trial
staff or health care worker, will be recorded and judged
by the study group and the independent physician. The
trial staff will convert reported symptoms to a standard
lexicon, the Common Terminology Criteria for Adverse
Events (CTCAE) [37], to facilitate international scientific
reporting. Adverse effects will be classified based on the
FDA guideline [29], as overt toxicity (for example, clin-
ical signs, macro- and microscopic lesions); surrogate
markers of toxicity (for example, plasma liver enzyme
levels); or other adverse effects. The ADR probability
scale [38] will be used to assess the causal relationship
between trial supplement use and any reported adverse
event. Adverse events will be followed until they have
abated, or until a stable situation has been reached. De-
pending on the event, follow-up may require additional
tests or medical procedures.
Retention and withdrawal of individual subjects
We will actively monitor retention, and once enrolled,
we will make every reasonable effort to follow the par-
ticipant for the entire study period. In the trial design,
we put great effort into limiting the participant’s burden
related to visits and procedures, including the calcula-
tion of an appropriate NOAEL and HED, and the pre-
dominant use of noninvasive assessments. Participants
will receive a financial compensation within the MERC
guidelines. However, subjects can leave the study at any
time for any reason without any consequences. Partici-
pants will be given the option to be followed up on cer-
tain outcome measures only, if this would lead to
retention. Nonadherence will in itself not be a reason to
exclude the participant. We will collect the reasons for
nonadherence and nonretention where possible. In
addition, the investigator can decide to withdraw asubject from the study for any medical reasons. Upon
withdrawal, subjects will be replaced.
Emergency unblinding
To ensure the overall quality of the trial, code breaks will
occur only when knowledge of the actual supplement
given is absolutely essential for further management of the
participant. This will be decided by the independent
physician.
Premature termination of the study
If, despite our expectations, any serious side effect is ob-
served in the volunteers, the study may be stopped
prematurely.
Quality control
We will ensure that quality controls will be executed
throughout the conduct of the study, with regard to par-
ticipant selection, data collection, data processing and
reporting. Additionally, trial staff who collect the data will
be well-trained according to standard operating proce-
dures, in the study requirements, use of the questionnaire,
counseling for adherence, standardized measurement of
height, weight, brachial blood pressure, electrocardio-
graphy and noninvasive hemodynamics, as well as for re-
quirements for laboratory specimen collection including
morning urine samples. On every day of the data collec-
tion, we will monitor and ascertain the performance of our
measurement devices. Our database was designed to allow
checks on the completeness of the entered data and basic
data checks, and we will use independent double data-
entry followed by matching and checking for data-entry er-
rors. Data cleaning will be performed according to expert
consensus. Finally, we will check internal and external
consistency of the analyzed data before writing reports.
Ethical considerations
The study will be conducted according to the principles
of the Declaration of Helsinki (Adopted by the 18th
WMA General Assembly, Helsinki, Finland, June 1964,
and amended by the 59th WMA General Assembly,
Seoul, October 2008), and in accordance with the Dutch
Medical Research Involving Human Subjects Act
(WMO). Prior to undertaking any study related proce-
dures, each participant will receive a verbal and written
explanation of study aims, methods, and potential side
effects. The participants will provide written informed
consent. The full study protocol is approved by the
AMC Amsterdam Medical Ethics Review Committee on 25
November 2013 (MERC reference number 38368.018.12).
All study-related information will be stored securely at the
study site and participants’ personal study information will
not be released without his written permission.
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Handling of personal data will comply with the Dutch
Personal Data Protection Act. Data will be entered an-
onymously in a database designed for the study, with a
code of which the key will be held by the clinical project
leader (LMB). The original study forms, extracted data,
and biological samples will be kept at the hospital for
15 years, with access restricted to the trial staff.
Discussion
Hypertension is still the main risk factor for premature
death [1]. Despite the ample availability of antihyperten-
sive drugs and the adequate use whereof, it is estimated
that around 10 to 30% of the hypertensive patients are
not controlled with currently available drug regimens.
Currently, there is an unfulfilled need for new conserva-
tive options to treat resistant hypertension [1-5].
This study is based on incremental data indicating that
the ATP regenerating enzyme creatine kinase enhances
the energy demanding processes involved in hyperten-
sion, including vascular contractility and salt retention,
and that the creatine analog and competitive CK inhibi-
tor GPA reduces blood pressure in animal studies
[5,6,8-16]. Hence, this is a first-in-men study of what
might become a new class of antihypertensive drugs. In
this study, we will collect data with close adherence to
the US FDA and European guidelines. We expect no dif-
ference in reported adverse effects between GPA, creat-
ine, and placebo. This study will increase the knowledge
on the effect of moderate reversible cytoplasmic creatine
kinase inhibition on the human cardiovascular system
and provide data on tolerability and hemodynamic pa-
rameters. Beta-guanidinopropionic acid doses are low,
aimed at preventing toxicity in this first-in-men study.
This limits the study of the efficacy of the drug.
Trial status
The trial is currently recruiting participants.
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